Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

20200303 BT-001 presentations EN

Published 3 March 2020
Categorized as 2020, BT-001, Press release

First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases

20200220 PR FPI 6002.03 EN

Published 20 February 2020
Categorized as 2020, Press release, TG6002

Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases

https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdfClémentine Spring-Giusti et al.American College of Toxicology – 40th Annual MeetingDownload the poster herePoster Presentation

Published 22 January 2020
Categorized as -others, 2020, Publication

Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers

20200107 PR TG4050 FPI – EN

Published 7 January 2020
Categorized as 2020, Press release, TG4050

Transgene Announces Financial Calendar for 2020

20191218 Financial calendar 2020 EN

Published 18 December 2019
Categorized as 2019, Press release

Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer

20191212 PR TG4010_EN_results

Published 12 December 2019
Categorized as 2019, Press release, TG4010

Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors

20191211 PR preclinical BT001 EN

Published 11 December 2019
Categorized as 2019, BT-001, Invir.IO, Press release

Transgene Announces Investor Meetings for January 2020

20191209 PR Investors Meeting agenda 2020

Published 9 December 2019
Categorized as 2019, Press release

Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases

https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdf Clémentine Spring-Giusti et al. American College of Toxicology – 40th Annual Meeting Download the poster here Poster Presentation

Published 17 November 2019
Categorized as -others, 2020, Publication

Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001

20191114 Résultats T3-2019 EN

Published 14 November 2019
Categorized as 2019, Press release

Posts pagination

Newer posts Page 1 … Page 27 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu